Get notified when TPST files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Delisting (new) — Company received two separate Nasdaq deficiency notices for failing stockholders' equity requirements and board independence standards, creating immediate delisting risk.
- Going Concern (new) — Company disclosed substantial doubt about its ability to continue as a going concern due to capital needs and liquidity constraints.
Tempest Therapeutics faces dual Nasdaq deficiency notices for equity shortfall and board crisis
Filed May 22, 2026 · Period ending May 19, 2026 · ~1 min read
Key Changes
-
high
Tempest's stockholders' equity of $822K falls $1.7M short of Nasdaq's $2.5M minimum requirement. Company has until July 6 to submit compliance plan and may receive up to 180 days to cure if accepted.
Item 3.01 verify on EDGAR → -
high
Board resignations triggered immediate Nasdaq non-compliance for lacking majority independent directors and proper audit, compensation, and nominating committee composition. Multiple vacancies make company ineligible for standard cure periods.
Item 3.01 verify on EDGAR → -
high
Company disclosed substantial doubt about ability to continue as going concern due to liquidity constraints and need for additional capital to fund operations.
8-K disclosure view on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ADMT 10-K) is open in full — no account needed.
Partner
Trade TPST commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · May 24, 2026 · How we verify